Evidence map›Paper›PMID 29718991›Full record

ArticlePLoS pathogens2018

A lipid-binding loop of botulinum neurotoxin serotypes B, DC and G is an essential feature to confer their exquisite potency.

Daniel Stern, Jasmin Weisemann, Alexander Le Blanc, Laura von Berg, Stefan Mahrhold, Janett Piesker, Michael Laue, Peter B Luppa, Martin Bernhard Dorner, Brigitte Gertrud Dorner and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Botulinum Neurotoxins: Mechanism of Action.Handbook of experimental pharmacology · 2021
    Review
  12. Article
  13. Article
  14. Review
  15. Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  16. Article
  17. Article
  18. Botulinum and Tetanus Neurotoxins.Annual review of biochemistry · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Daniel SternBiological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.ORCID 0000-0001-9057-4283
Jasmin WeisemannInstitut für Toxikologie, Medizinische Hochschule Hannover, Hannover, Germany.
Alexander Le BlancInstitute for Clinical Chemistry and Pathobiochemistry, Klinikum rechts der Isar, Technische Universität München, München, Germany.
Laura von BergBiological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.ORCID 0000-0002-3360-5917
Stefan MahrholdInstitut für Toxikologie, Medizinische Hochschule Hannover, Hannover, Germany.
Janett PieskerAdvanced Light and Electron Microscopy (ZBS 4), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
Michael LaueAdvanced Light and Electron Microscopy (ZBS 4), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.ORCID 0000-0002-6474-9139
Peter B LuppaInstitute for Clinical Chemistry and Pathobiochemistry, Klinikum rechts der Isar, Technische Universität München, München, Germany.
Martin Bernhard DornerBiological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.ORCID 0000-0002-8176-797X
Brigitte Gertrud DornerBiological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
Andreas RummelInstitut für Toxikologie, Medizinische Hochschule Hannover, Hannover, Germany.ORCID 0000-0002-0645-1641
Robert Koch Institute · DEMedizinische Hochschule Hannover · DETUM Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The exceptional toxicity of botulinum neurotoxins (BoNTs) is mediated by high avidity binding to complex polysialogangliosides and intraluminal segments of synaptic vesicle proteins embedded in the presynaptic membrane. One peculiarity is an exposed hydrophobic loop in the toxin's cell binding domain HC, which is located between the ganglioside- and protein receptor-binding sites, and that is particularly pronounced in the serotypes BoNT/B, DC, and G sharing synaptotagmin as protein receptor. Here, we provide evidence that this HC loop is a critical component of their tripartite receptor recognition complex. Binding to nanodisc-embedded receptors and toxicity were virtually abolished in BoNT mutants lacking residues at the tip of the HC loop. Surface plasmon resonance experiments revealed that only insertion of the HC loop into the lipid-bilayer compensates for the entropic penalty inflicted by the dual-receptor binding. Our results represent a new paradigm of how BoNT/B, DC, and G employ ternary interactions with a protein, ganglioside, and lipids to mediate their extraordinary neurotoxicity.

Indexed as

AnimalsBinding SitesBotulinum ToxinsBotulinum Toxins, Type ACarrier ProteinsCell MembraneCrystallography, X-RayGangliosidesHydrophobic and Hydrophilic InteractionsLipidsMembrane GlycoproteinsMiceProtein BindingProtein ConformationReceptors, NeurotransmitterSerogroupBotulinum ToxinsBotulinum Toxins, Type Abotulinum toxin type Dbotulinum toxin type GCarrier ProteinsGangliosidesLipidsMembrane GlycoproteinsReceptors, NeurotransmitterrimabotulinumtoxinBtrisialoganglioside GT1

Identifiers

PMID29718991
PMCPMC5951583
OpenAlexW2800160461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.